Grupo Ferrer Internacional, S.A.

Industry

  • Pharmaceuticals
    • Generic Drugs
    • Drug Delivery
    • Nutraceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products
  • Medical Devices
  • In Vitro Diagnostics

Other Names/Subsidiaries

  • Addicere Therapeutics, Inc.
  • Alexza Pharmaceuticals, Inc.
See more in Biomedtracker

Latest on Grupo Ferrer Internacional, S.A.

Scrip

FibroGen’s Roxadustat On The Rocks After Phase III Myelodysplastic Syndrome Failure

 
• By Alaric DeArment

The failure of FibroGen, Inc. ’s Phase III MATTERHORN trial of roxadustat in anemia among patients with transfusion-dependent lower-risk myelodysplastic syndrome (MDS) likely seals the drug’s fate in

Scrip

Deal Watch: AbbVie Adds Neuroscience Heft With Syndesi Acquisition

 
• By Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Continues Development Of Novel S

Scrip

Catalan Biotechs Boosted By International Backers

 
• By Kevin Grogan

Catalonia’s biotech sector has continued to boom despite the political storms that struck the region and the rest of Spain just over a year ago and foreign and domestic investment is on the rise. Bioc

Scrip

Deal Watch: Ionis Turns To Affiliate Akcea In Amyloidosis

 
• By Joseph Haas, Anju Ghangurde, John Davis, and Kevin Grogan

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in